17 news items
Peeling Back The Layers: Exploring Bristol-Myers Squibb Through Analyst Insights
BMY
26 Apr 24
on the current state of the company.
Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY
26 Apr 24
of overall survival (OS) and progression-free survival (PFS) as assessed by Blinded Independent Central Review (BICR). With a median follow up
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY
25 Apr 24
as assessed
Bristol Myers Squibb's Acquired Adagrasib Combo Therapy May Benefit Colorectal Cancer Patients With Certain Mutation
BMY
8 Apr 24
of overall response rate.
The study remains ongoing to assess the additional key secondary endpoint of overall survival.
In 2022
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
BMY
6 Apr 24
meaningful changes in movement disorder scale scores over 52 weeks (Oral Session: New Pharmacological Treatments and Assessments and Poster F74
8in jzf7rucnrby
BMY
2 Apr 24
assessment to understand evolving stakeholder views and ensure its business priorities
c1fbuddrye wyvfe9
BMY
ZLAB
1 Apr 24
).
The study remains ongoing to assess the additional key secondary endpoint of overall survival.
Results showed that Krazati
eo8m1ucu 7ch
BMY
CATX
LNTH
28 Mar 24
feasibility assessments on additional sites.Preliminary results from Cohorts 1 and 2 of the Phase 1/2a trial are expected in the third
eqi1qvqi30tukr6yrd1ulkwsidh5dp334hia0ytpeog3r2skmf
BMY
25 Mar 24
.
Echocardiogram assessments of LVEF are required prior to and during treatment with CAMZYOS. Initiation of CAMZYOS in patients
ya18m 39n
BMY
14 Mar 24
escalation portion of the study assessed the safety and recommended dose for the subsequent Phase 2 expansion cohort. The Phase 2 portion of the study
62kradczzocnb2f6r0czv79sbr264wnf47
BMY
7 Mar 24
overall survival (OS) and progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR
zg9cyhe p0
BMY
29 Feb 24
.
Additionally, a separate analysis (Poster #P097) was conducted to assess the risk of rebound after
- Prev
- 1
- Next